Physician profile
Thomas E Rogers
NPI 1891798575
$6,076.56
in general payments reported to CMS, 2019-2025
27 companies · $623 in 2025
The $623 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $1,111 · 2021: $1,313 · 2022: $1,182 · 2023: $850 · 2024: $522 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,986.30 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,754.73 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $534.10 | 2020-2024 | Zepbound, Mounjaro, Jardiance |
| Merz North America, INC. | $411.36 | 2019-2020 | |
| Abbvie INC. | $391.91 | 2020-2025 | Ubrelvy |
| Idorsia Pharmaceuticals US INC | $322.04 | 2022-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $254.84 | 2019-2021 | |
| Allergan, INC. | $240.82 | 2019-2022 | |
| Globus Medical, INC. | $218.68 | 2025 | Omnia |
| Axsome Therapeutics, INC. | $194.26 | 2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $125.89 | 2020-2023 | Trintellix |
| Galderma Laboratories, L.P. | $97.78 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $77.13 | 2021 | |
| Clarus Therapeutics INC. | $71.63 | 2021 | |
| Corcept Therapeutics | $62.69 | 2025 | Korlym |
| Revance Therapeutics, INC. | $60.79 | 2024 | Daxxify |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $47.02 | 2023-2024 | NP Thyroid 60 |
| Insulet Corporation | $32.70 | 2024-2025 | Omnipod |
| Supernus Pharmaceuticals, INC. | $24.45 | 2023 | Qelbree |
| Xeris Pharmaceuticals, INC. | $23.50 | 2024 | Gvoke Hypopen |
| Romark Laboratories, Lc | $22.36 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $20.31 | 2023 | Verquvo, Belsomra |
| Eisai INC. | $16.30 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.23 | 2023 | Edarbyclor |
| Exact Sciences Corporation | $15.29 | 2025 | The Cologuard Plus Collection Kit |
| Antares Pharma, INC. | $14.00 | 2021 | |
| Tolmar, INC. | $13.29 | 2024 | |
| Amarin Pharma, INC. | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.